Amir Sonnenblick

Summary

Publications

  1. ncbi Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, P O Box 12000, Jerusalem, 91120, Israel
    Breast Cancer Res Treat 138:407-13. 2013
  2. ncbi Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, POB 12000, Ein Kerem, Jerusalem, 91120, Israel
    Med Oncol 29:3035-8. 2012
  3. ncbi Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, POB 12000, Jerusalem 91120, Israel
    Clin Transl Oncol 14:232-6. 2012
  4. ncbi Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature
    Amir Sonnenblick
    Oncology Department, Hadassah Hebrew University Medical Center, Ein Kerem, POB 12000, 91120 Jerusalem, Israel
    Int J Clin Oncol 15:420-2. 2010
  5. ncbi Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel
    Cancer Biol Ther 12:165-8. 2011
  6. ncbi [Update: adjuvant trastuzumab in HER2 positive breast cancer]
    Esther Tahover
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Harefuah 151:37-42, 61. 2012

Collaborators

Detail Information

Publications6

  1. ncbi Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, P O Box 12000, Jerusalem, 91120, Israel
    Breast Cancer Res Treat 138:407-13. 2013
    ..Whether phospho-STAT3 has a predictive role of benefit from adjuvant chemotherapy has to be validated on prospective, randomized, controlled studies...
  2. ncbi Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, POB 12000, Ein Kerem, Jerusalem, 91120, Israel
    Med Oncol 29:3035-8. 2012
    ..302 and P = 0.707, respectively). In conclusion, long-term follow-up demonstrates that postoperative chemoradiation with combination of bolus 5-fluorouracil, continuous 5-fluorouracil, and cisplatin is a feasible approach...
  3. ncbi Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, POB 12000, Jerusalem 91120, Israel
    Clin Transl Oncol 14:232-6. 2012
    ..The goal of this study was to determine the prognostic value of phosphorylated (tyrosine705)-STAT3 in node-positive breast cancer patients...
  4. ncbi Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature
    Amir Sonnenblick
    Oncology Department, Hadassah Hebrew University Medical Center, Ein Kerem, POB 12000, 91120 Jerusalem, Israel
    Int J Clin Oncol 15:420-2. 2010
    ..Oncologists should therefore be aware of the potential for RTA to occur after capecitabine, oxaliplatin, and cetuximab treatment, especially in the context of other predisposing factors...
  5. ncbi Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel
    Cancer Biol Ther 12:165-8. 2011
    ..This may be applied also to other metastatic tumors diagnosed in BRCA1/2 carriers...
  6. ncbi [Update: adjuvant trastuzumab in HER2 positive breast cancer]
    Esther Tahover
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Harefuah 151:37-42, 61. 2012
    ..In this review we summarize the current perspective on Trastuzumab and discuss adjuvant treatments in HER2-positive early breast cancer...